Search results
Results from the WOW.Com Content Network
On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid ...
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without ...
On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis ...
Vir Biotechnology, Inc. (VIR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ...
Do the numbers hold clues to what lies ahead for the stock? Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 167.65% and 205.95%, respectively, for the quarter ended June ...
For premium support please call: 800-290-4726 more ways to reach us
SVB Leerink initiated coverage on Vir Biotechnology Inc (NASDAQ: VIR) with an Outperform rating and a price target of $40, with an investment thesis based on: With multiple clinic programs, Vir is ...
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...